<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340779</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001270-41</org_study_id>
    <nct_id>NCT03340779</nct_id>
  </id_info>
  <brief_title>Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock</brief_title>
  <acronym>SHOCK-NORDOB</acronym>
  <official_title>Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock is a frequent cause of admission and death in the intensive care unit.

      Mortality is about 50%. Once the etiologic treatment has been done, for instance coronary
      revascularization, management of the shock state is the cornerstone of the treatment.
      Norepinephrine is the first-line vasopressor therapy because of its minor effect on heart
      rhythm. Morever norepinephrine is a inotrope. In a previous study, we demonstrated that
      increasing the norepinephrine dose increases cardiac index, cardiac power index, SVO2 and
      tissue perfusion without acceleration of heart rate. Nevertheless, dobutamine remains the
      first-line inotropic treatment. Dobutamine has a positive chronotropic effect that might
      cause higher myocardial oxygen consumption. As a result, combination of vasopressor /
      inotrope is still controversial.

      The aim of this study was to compare hemodynamics and metabolics effects of 2 treatments
      strategies (norepinephrine dose increasing or addition of dobutamine) in patients with
      cardiogenic shock and optimised blood pressure level (MAP≥65 mmHg) under norepinephrine
      treatment.

      The secondary objectives were :

        -  To evaluate the efficacy of the treatments on micro- and macrocirculation parameters

        -  To evaluate the tolerance of the treatments

        -  To evaluate the dose and the admistration's kinetics of the treatments
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3 first hours : strategy 1, norepinephrine alone with increased dose or norepinephrine + dobutamine 0.5 hour : wash-out (decrease of norepinephrine dose or weaning of dobutamine) 3 last hours : strategy 2, crossover, norepinephrine alone with increased dose or norepinephrine + dobutamine</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obtention of a optimal cardiac output</measure>
    <time_frame>Hour 0 (H0), Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Measure of increase of cardiac index &gt; 15% (L/min/m²), increase of organ perfusion assessed by : lactate clearance &gt; 15% (mmoL/L), decrease of mottling (decrease of 2 points of Mottling score), increase of musculaire oxygen saturation measured by NIRS &gt; 15% (rSo2%), increase of urine output &gt; 50% (mL/h), increase of SVcO2 &gt; 15%(%)
Evaluation of occurence of side effects :
Increase of heart rate &gt; 15% (bpm) , increase of oxygen consumption evaluated by decrease of ratio mean arterial pressure / heart rate &gt; 15% (Buffington ratio).
The primary endpoint is defined by the presence of 2 efficacy criterias without any side effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Measure of heart rate (bpm),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrythmia</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Notification of atrial arrythmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Cumulated dose of catecholamines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Arterial blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>SVcO2 (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Lactate clearance (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Muscular oxygen saturation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Urine output (mL/h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic parameters</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Mottle (mottle score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of arrythmia</measure>
    <time_frame>Hour 0, Hour 1, Hour 3, Hour 3.5, Hour 4,5, Hour 5.5, Hour 6.5</time_frame>
    <description>Notification of ventricular arrythmia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Norepinephrine alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of norepinephrine with increasing dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine plus Dobutamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of norepinephrine and dobutamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.</description>
    <arm_group_label>Norepinephrine alone</arm_group_label>
    <arm_group_label>Norepinephrine plus Dobutamine</arm_group_label>
    <other_name>Dobutamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with cardiogenic shock (ischemic, rythmic, valvular) defined : by cardiac
             index (CI) &lt; 2,2 L/min/m² or CI &lt; 2,5 L/min/m² under vasopressor/inotropic treatment
             and organ hypoperfusion signs : mottles, capillary refill time , urine output &lt; 0,5
             mL/kg/hour during at least one hour ou renal replacement therapy, consciouness
             impairment, pulmonary oedema, hyperlactatemia (&gt; 2 mmoL/L)

          -  Mean arterial pressure &gt; 65 mmHg under norepinephrine treatment

          -  Patients with social coverage

        Exclusion Criteria:

          -  &lt; 18 years old

          -  Pregnancy

          -  Inclusion in other drug study

          -  Poisonings with cardiotoxicants

          -  Patient with intra-aortic ballon pump, extracorporeal life support

          -  Patient under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Nancy-Brabois</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Auchet, MD</last_name>
      <phone>033383157022</phone>
      <email>t.auchet@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norepinephrine</keyword>
  <keyword>Dobutamine</keyword>
  <keyword>Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Dobutamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

